This study is looking at a treatment plan for people with Stage 3 non-small cell lung cancer (NSCLC) that has spread to certain lymph nodes (N3 involvement). The main goal is to see if surgery to remove the cancer is possible after you receive a combination of chemotherapy and an immunotherapy drug called cemiplimab-rwlc. You would receive four treatments of this three-drug combination every three weeks before surgery. After surgery, you would continue to receive cemiplimab-rwlc every three weeks for one year. The study is trying to find out how many patients have a complete response to the treatment before surgery. To join, you must be at least 18 years old and have this specific type of lung cancer.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 21 participants.

What's involved

You would receive a three-drug combination every three weeks for four cycles before surgery. After surgery, you would receive cemiplimab-rwlc every three weeks for one year.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, pathologic complete response, is measured at 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.